Akorn Faces Hurdles In Returning To Path Of Profitable Growth

 
• By Aidan Fry

A new management team at Akorn is making progress on moving on from Fresenius Kabi’s ill-fated takeover bid; but putting manufacturing problems behind the US injectables and ophthalmics specialist is proving difficult.

Trees
Akorn is far from finding its way out of the woods on FDA manufacturing compliance issues • Source: Shutterstock

More from Earnings

More from Business